EB-TCIP

• Description :

  EB-TCIP (BAK-04-212) is a bivalent molecule comprised of AP1867 (HY-114434) and BI-3812 (HY-111381) . EB-TCIP can form a reversible ternary complex between FKBPF36V and BCL6BTB. EB-TCIP recruits FKBP12F36V-tagged EWS/FLI1 to DNA sites bound by the transcriptional regulator BCL6, leading to rapid expression of BCL6 target genes (eg: SOCS2 and CXCL11) . EWS/FLI1 is a fusion transcription factors in Ewing sarcoma. EB-TCIP can be used for research of deregulated transcription in cancer[1].

• Product Name Alternative :

  BAK-04-212

• UNSPSC :

  12352005

• Target :

  BCL6

• Related Pathways :

  Immunology/Inflammation

• Field of Research :

  Cancer

• Purity :

  99.58

• Solubility :

  DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  COC1=C(OC)C(OC)=CC([C@@H](C(N2CCCC[C@H]2C(O[C@@H](C3=CC=CC=C3OCC(NCCCCCCNC(C4CCN(C5=NC(NC6=CC(C=C(OCC(NC)=O)C(N7C)=O)=C7C(OC)=C6)=C(Cl)C=N5)CC4)=O)=O)CCC8=CC=C(OC)C(OC)=C8)=O)=O)CC)=C1

• Molecular Formula :

  C68H86ClN9O15

• Molecular Weight :

  1304.91

• References & Citations :

  [1]Bond MJ, et al. Rewiring the fusion oncoprotein EWS/FLI1 in Ewing sarcoma with bivalent small molecules. bioRxiv [Preprint]. 2025 Mar 17:2025.03.14.643353.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported